Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users

References

• Aday, J. S., C. M. Mitzkovitz, E. K. Bloesch, C. C. Davoli, and A. K. Davis. 2020. Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews 113:179–89. doi:10.1016/j.neubiorev.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., and R. R. Griffiths. 2018. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Current Topics in Behavioral Neurosciences 36:393–430. doi:10.1007/7854_2017_474.
   PubMedGoogle Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Berkovitch, L., B. Roméo, L. Karila, R. Gaillard, and A. Benyamina. 2021. Efficacy of psychedelics in psychiatry, a systematic review of the literature. L’Encephale 47 (4):376–87. doi:10.1016/j.encep.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry 78 (5):481–89. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Doblin, Rick. (1991). Pahnke's Good Friday experiment: a long-term followup and methodological critique. Journal of Transpersonal Psychology 23
   Google Scholar
• Gandy, S. 2019. Psychedelics and potential benefits in “healthy normals”: A review of the literature. Journal of Psychedelic Studies 3 (3):280–87. doi:10.1556/2054.2019.029.
   Google Scholar
• Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33 (9):1088–101. doi:10.1177/0269881119845793.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, E. Erowid, F. Erowid, R. R. Griffiths, and M. W. Johnson. 2020. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry 10 (January):1–16. doi:10.3389/fpsyt.2019.00955.
   Web of Science ®Google Scholar
• Garcia-Romeu, A., R. R. Griffiths, and M. W. Johnson. 2014. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7 (3):157–64. doi:10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Goldberg, S. B., B. Shechet, C. R. Nicholas, C. W. Ng, G. Deole, Z. Chen, and C. L. Raison. 2020. Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis. Psychological Medicine 50 (16):2655–66. doi:10.1017/S003329172000389X.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218 (4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, M. W. Johnson, U. D. McCann, and R. Jesse. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22 (6):621–32. doi:10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Grolemund, G., and H. Wickham. 2011. Dates and times made easy with lubridate. Journal of Statistical Software 40 (3):1–25. https://www.jstatsoft.org/v40/i03/.
   Web of Science ®Google Scholar
• Haijen, E. C. H. M., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, et al. 2018. Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology 9 (NOV):897. doi:10.3389/fphar.2018.00897.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2016. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30 (12):1259–67. doi:10.1177/0269881116677852.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2017. Constructing drug effects: A history of set and setting. Drug Science, Policy and Law 3:205032451668332. doi:10.1177/2050324516683325.
   Google Scholar
• Hervé, M. 2021. Aide-mémoire de statistique appliquée à la biologie – Construire son étude et analyser les résultats à l’aide du logiciel R[French]. Accessed 4 April 2022 (available on CRAN). https://cran.r-project.org/doc/contrib/Herve-Aide-memoire-statistique.pdf
   Google Scholar
• Hood, R. W. 1975. The construction and preliminary validation of a measure of reported mystical experience. Journal for the Scientific Study of Religion 14 (1):29. doi:10.2307/1384454.
   Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, P. S. Johnson, and R. R. Griffiths. 2017. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology 31 (7):841–50. doi:10.1177/0269881116684335.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., P. S. Hendricks, F. S. Barrett, and R. R. Griffiths. 2019. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology and Therapeutics 197:83–102. doi:10.1016/j.pharmthera.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Kangaslampi, S., A. Hausen, and T. Rauteenmaa. 2020. Mystical experiences in retrospective reports of first times using a psychedelic in Finland. Journal of Psychoactive Drugs 52 (4):309–18. doi:10.1080/02791072.2020.1767321.
   PubMed Web of Science ®Google Scholar
• Leary, T., G. H. Litwin, and R. Metzner. 1963. Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease 137 (6):561–73. doi:10.1097/00005053-196312000-00007.
   PubMed Web of Science ®Google Scholar
• Luoma, J. B., C. Chwyl, G. J. Bathje, A. K. Davis, and R. Lancelotta. 2020. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs 1–11. doi:10.1080/02791072.2020.1769878.
   Web of Science ®Google Scholar
• Maclean, K. A., J.-M. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Muttoni, S., M. Ardissino, and C. John. 2019. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders 258 (April):11–24. doi:10.1016/j.jad.2019.07.076.
   PubMed Web of Science ®Google Scholar
• Preller, K. H., and F. X. Vollenweider. 2018. Phenomenology, structure, and dynamic of psychedelic states. Current Topics in Behavioral Neurosciences 36:221–56. doi:10.1007/7854_2016_459.
   PubMedGoogle Scholar
• R Core Team. 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available online at https://www.R-project.org/.
   Google Scholar
• Revelle, W. 2009. An introduction to psychometric theory with applications in R. Springer. https://personality-project.org/r/book/.
   Google Scholar
• Romeo, B., M. Hermand, A. Pétillion, L. Karila, and A. Benyamina. 2021. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Journal of Psychiatric Research 137:273–82. Elsevier Ltd. doi:10.1016/j.jpsychires.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Romeo, B., L. Karila, C. Martelli, and A. Benyamina. 2020. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology 026988112091995. doi:10.1177/0269881120919957.
   Web of Science ®Google Scholar
• Rosseel, Y. 2012. Lavaan: An R package for structural equation modeling. Journal of Statistical Software [English]. 48 (2):1–36. Accessed 4 April2022. http://www.jstatsoft.org/v48/i02/
   Web of Science ®Google Scholar
• Schmid, Y., and M. E. Liechti. 2018. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology 235 (2):535–45. doi:10.1007/s00213-017-4733-3.
   PubMed Web of Science ®Google Scholar
• Studerus, E., M. Kometer, F. Hasler, and F. X. Vollenweider. 2011. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology 25 (11):1434–52. doi:10.1177/0269881110382466.
   PubMed Web of Science ®Google Scholar
• Sueur, C. 2017. État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle. Psychotropes 23 (3):125. doi:10.3917/psyt.233.0125.
   Google Scholar
• Swanson, L. R. 2018. Unifying theories of psychedelic drug effects. Frontiers in Pharmacology 9:172. doi:10.3389/fphar.2018.00172.
   PubMed Web of Science ®Google Scholar
• Vollenweider, F. X., and K. H. Preller. 2020. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience 21:611–24. doi:10.1038/s41583-020-0367-2.
   PubMed Web of Science ®Google Scholar
• Wheeler, S. W., and N. L. Dyer. 2020. A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory Research, and Practice 7 (3):279–315. doi:10.1037/cns0000237.
   Google Scholar